{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:27:29Z","timestamp":1791822449631,"version":"4.3.4"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A history of pre-administration of immune checkpoint inhibitors has been reported to be associated with good outcomes of ramucirumab (RAM) plus docetaxel (DOC) combination therapy for advanced non-small-cell lung cancer (NSCLC). However, existing knowledge on the clinical significance of RAM and DOC following combined chemoimmunotherapy is limited. Therefore, we evaluated the efficacy and safety of RAM plus DOC therapy after combined chemoimmunotherapy and attempted to identify the predictors of its outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>This multicenter, prospective study investigated the efficacy and safety of RAM plus DOC after combined chemoimmunotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence of adverse events. An exploratory analysis measured serum cytokine levels at the start of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 44 patients were enrolled from 10 Japanese institutions between April 2020 and June 2022. The median PFS and OS were 6.3 and 22.6 months, respectively. Furthermore, the ORR and DCR were 36.4% and 72.7%, respectively. The high vascular endothelial growth factor D (VEGF-D) group had a significantly shorter PFS and OS. A combination of high VEGF-A and low VEGF-D levels was associated with a longer PFS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our results showed that RAM plus DOC after combined chemoimmunotherapy might be an effective and relatively feasible second-line treatment for patients with advanced NSCLC in a real-world setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae001","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T17:50:18Z","timestamp":1705686618000},"page":"e681-e689","source":"Crossref","is-referenced-by-count":6,"title":["Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9209-4267","authenticated-orcid":false,"given":"Yuki","family":"Katayama","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-281X","authenticated-orcid":false,"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Kawachi","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences , Niigata , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kageaki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-844X","authenticated-orcid":false,"given":"Yusuke","family":"Chihara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Uji-Tokushukai Medical Center , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Shiotsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hibino","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital , Kanagawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fukuchiyama City Hospital , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iwasaku","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsaku","family":"Tokuda","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"2024050313082885800_CIT0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume-title":"CA Cancer J Clin","author":"Sung","year":"2021"},{"key":"2024050313082885800_CIT0002","first-page":"1627","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume-title":"N Engl J Med","author":"Borghaei","year":"2015"},{"key":"2024050313082885800_CIT0003","first-page":"1540","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume-title":"Lancet","author":"Herbst","year":"2016"},{"key":"2024050313082885800_CIT0004","first-page":"255","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume-title":"Lancet","author":"Rittmeyer","year":"2017"},{"key":"2024050313082885800_CIT0005","first-page":"2078","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume-title":"N Engl J Med","author":"Gandhi","year":"2018"},{"key":"2024050313082885800_CIT0006","first-page":"2288","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume-title":"N Engl J Med","author":"Socinski","year":"2018"},{"key":"2024050313082885800_CIT0007","first-page":"198","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume-title":"Lancet Oncol","author":"Paz-Ares","year":"2021"},{"key":"2024050313082885800_CIT0008","first-page":"1187","article-title":"Targeted inhibition of VEGF receptor 2: an update on ramucirumab","volume-title":"Expert Opin Biol Ther","author":"Clarke","year":"2013"},{"key":"2024050313082885800_CIT0009","first-page":"665","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume-title":"Lancet","author":"Garon","year":"2014"},{"key":"2024050313082885800_CIT0010","first-page":"1956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment","volume-title":"Front Immunol","author":"Song","year":"2020"},{"key":"2024050313082885800_CIT0011","first-page":"316","article-title":"Tumor neovascularization and developments in therapeutics","volume-title":"Cancers (Basel)","author":"Katayama","year":"2019"},{"key":"2024050313082885800_CIT0012","first-page":"450","article-title":"Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients","volume-title":"Transl Lung Cancer Res","author":"Yoshimura","year":"2019"},{"key":"2024050313082885800_CIT0013","first-page":"4987","article-title":"Previous immune checkpoint inhibitor treatment to increase the efficacy of docetaxel and ramucirumab combination chemotherapy","volume-title":"Anticancer Res","author":"Harada","year":"2019"},{"key":"2024050313082885800_CIT0014","first-page":"e000350","article-title":"Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)","volume-title":"J ImmunoTher Cancer","author":"Kato","year":"2020"},{"key":"2024050313082885800_CIT0015","first-page":"71","article-title":"Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1\/PD-L1 treatment","volume-title":"Lung Cancer","author":"Tozuka","year":"2020"},{"key":"2024050313082885800_CIT0016","first-page":"85","article-title":"Nivolumab in NSCLC: latest evidence and clinical potential","volume-title":"Ther Adv Med Oncol","author":"Sundar","year":"2015"},{"key":"2024050313082885800_CIT0017","first-page":"3585","article-title":"Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody","volume-title":"Thorac Cancer","author":"Murakami","year":"2020"},{"key":"2024050313082885800_CIT0018","first-page":"62","article-title":"Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)","volume-title":"Eur J Cancer","author":"Nakamura","year":"2023"},{"key":"2024050313082885800_CIT0019","first-page":"452","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume-title":"Bone Marrow Transplant","author":"Kanda","year":"2013"},{"key":"2024050313082885800_CIT0020","first-page":"S68","article-title":"46P Multi-center, phase II study of docetaxel (DTX) plus ramucirumab (RAM) following platinum-based chemotherapy plus ICIs in patients with NSCLC: SCORPION study","volume-title":"J Thoracic Oncol","author":"Matsuzawa","year":"2023"},{"key":"2024050313082885800_CIT0021","first-page":"186","article-title":"A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy","volume-title":"Lung Cancer","author":"Yoh","year":"2016"},{"key":"2024050313082885800_CIT0022","first-page":"1321","article-title":"Increased VEGF-A in solid type of lung adenocarcinoma reduces the patients\u2019 survival","volume-title":"Sci Rep","author":"Jung","year":"2021"},{"key":"2024050313082885800_CIT0023","first-page":"4228","article-title":"Synchronous vascular endothelial growth factor protein profiles in both tissue and serum identify metastasis and poor survival in colorectal cancer","volume-title":"Sci Rep","author":"Yeh","year":"2019"},{"key":"2024050313082885800_CIT0024","first-page":"584","article-title":"Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer","volume-title":"BMC Cancer","author":"Sopo","year":"2019"},{"key":"2024050313082885800_CIT0025","first-page":"175","article-title":"The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses\u2019 Health Study","volume-title":"Breast Cancer Res Treat","author":"Liu","year":"2011"},{"key":"2024050313082885800_CIT0026","first-page":"12234","article-title":"Distinct circulating cytokine\/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non-small cell lung cancer","volume-title":"Cancer Med","author":"Hu","year":"2023"},{"key":"2024050313082885800_CIT0027","first-page":"49","article-title":"Cancer combination therapies by angiogenesis inhibitors; a comprehensive review","volume-title":"Cell Commun Signal","author":"Ansari","year":"2022"},{"key":"2024050313082885800_CIT0028","first-page":"481","article-title":"VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis","volume-title":"Breast Cancer Res Treat","author":"Santos","year":"2015"},{"key":"2024050313082885800_CIT0029","first-page":"978","article-title":"Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma","volume-title":"BMC Cancer","author":"Amano","year":"2021"},{"key":"2024050313082885800_CIT0030","first-page":"602","article-title":"Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study","volume-title":"Ann Oncol","author":"Tabernero","year":"2018"},{"key":"2024050313082885800_CIT0031","first-page":"978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume-title":"Front Immunol","author":"Yang","year":"2018"},{"key":"2024050313082885800_CIT0032","first-page":"4762","article-title":"Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C\/D receptor VEGFR-3","volume-title":"EMBO J","author":"M\u00e4kinen","year":"2001"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/5\/e681\/57396247\/oyae001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/5\/e681\/57396247\/oyae001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T13:08:39Z","timestamp":1714741719000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/5\/e681\/7577447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,1,18]]},"published-print":{"date-parts":[[2024,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae001","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,1,18]]}}}